Pfizer’s Ruxience Rituximab Biosimilar Gets CHMP Nod
Positive Opinions Also Issued For Hybrids And Generics
Pfizer has received a positive opinion from the CHMP recommending granting a pan-European marketing authorization for its Ruxience rituximab biosimilar version of MabThera. At the same time, CHMP nods for hybrid medicines were received by SciPharm and Teva, while Mylan, Betapharm and Accord saw generics endorsed by the committee.
